Pure Global

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) - Trial NCT03061214

Access comprehensive clinical trial information for NCT03061214 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 868 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT03061214
Phase 3
Completed
drug
Trial Details
ClinicalTrials.gov • NCT03061214
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial

Study Focus

Semaglutide 0.5 mg

Interventional

drug

Sponsor & Location

Novo Nordisk A/S

Aparecida de Goiania,Porto Alegre,São Paulo,Hefei,Hefei,Beijing,Beijing,Beijing,Beijing,Beijing,ChongQing,Fuzhou,Guangzhou,Guangzhou,Guangzhou,Zhuhai,Guiyang,Qiqihar,Chenzhou,Changzhou,Nanjing,Nanjing, Brazil,China,China,South Korea,South Africa,Taiwan,Ukraine

Timeline & Enrollment

Phase 3

Aug 28, 2017

Apr 15, 2019

868 participants

Primary Outcome

Change in HbA1c

Summary

This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to
 compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin
 100 mg once-daily on glycaemic control after 30 weeks of treatment. Subjects will remain on
 their stable pre-trial metformin.

ICD-10 Classifications

Type 2 diabetes mellitus
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT03061214

Non-Device Trial